Bioequivalence and Bioavailability Forum

Hi xpresso & welcome to the club!

I think that you are overdoing it.
If you have multiple PK metrics and all must pass (that’s the regulatory requirement) at level \(\small{\alpha}\) – in general 0.05 – you are protected against inflation of the type I error by the intersection-union principle.¹ No need for simulations,² simply calculate power for given T/R-ratio, CV, and the sample size. If any of the metrics shows power <50%, the study will fail (see this article).

---

1. Berger RL, Hsu JC. Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Sets. Stat Sci. 1996; 11(4): 283–302. JSTOR:2246021.
   
2. Zeng A. The TOST confidence intervals and the coverage probabilities with R simulation. March 14, 2014. Online.